132 related articles for article (PubMed ID: 16675176)
1. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery.
Meissner Y; Pellequer Y; Lamprecht A
Int J Pharm; 2006 Jun; 316(1-2):138-43. PubMed ID: 16675176
[TBL] [Abstract][Full Text] [Related]
2. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles.
Lamprecht A; Yamamoto H; Takeuchi H; Kawashima Y
J Control Release; 2005 May; 104(2):337-46. PubMed ID: 15907584
[TBL] [Abstract][Full Text] [Related]
3. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease.
Pertuit D; Moulari B; Betz T; Nadaradjane A; Neumann D; Ismaïli L; Refouvelet B; Pellequer Y; Lamprecht A
J Control Release; 2007 Nov; 123(3):211-8. PubMed ID: 17889397
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
Lamprecht A; Ubrich N; Yamamoto H; Schäfer U; Takeuchi H; Maincent P; Kawashima Y; Lehr CM
J Pharmacol Exp Ther; 2001 Nov; 299(2):775-81. PubMed ID: 11602694
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.
Lamprecht A; Yamamoto H; Takeuchi H; Kawashima Y
J Pharmacol Exp Ther; 2005 Oct; 315(1):196-202. PubMed ID: 15980057
[TBL] [Abstract][Full Text] [Related]
6. Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus.
Lamprecht A; Yamamoto H; Takeuchi H; Kawashima Y
Eur J Pharm Biopharm; 2004 Jul; 58(1):37-43. PubMed ID: 15207535
[TBL] [Abstract][Full Text] [Related]
7. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis.
Moulari B; Pertuit D; Pellequer Y; Lamprecht A
Biomaterials; 2008 Dec; 29(34):4554-60. PubMed ID: 18790531
[TBL] [Abstract][Full Text] [Related]
8. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice.
Pellequer Y; Meissner Y; Ubrich N; Lamprecht A
J Pharmacol Exp Ther; 2007 May; 321(2):726-33. PubMed ID: 17322027
[TBL] [Abstract][Full Text] [Related]
9. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
10. FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.
Lamprecht A; Yamamoto H; Ubrich N; Takeuchi H; Maincent P; Kawashima Y
Pharm Res; 2005 Feb; 22(2):193-9. PubMed ID: 15783066
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
[TBL] [Abstract][Full Text] [Related]
12. Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis.
Kietzmann D; Moulari B; Béduneau A; Pellequer Y; Lamprecht A
Eur J Pharm Biopharm; 2010 Oct; 76(2):290-5. PubMed ID: 20600885
[TBL] [Abstract][Full Text] [Related]
13. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
McCarron PA; Marouf WM; Donnelly RF; Scott C
J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
[TBL] [Abstract][Full Text] [Related]
14. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T
J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845
[TBL] [Abstract][Full Text] [Related]
15. Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease.
Tenikoff D; Murphy KJ; Le M; Howe PR; Howarth GS
J Gastroenterol; 2005 Apr; 40(4):361-5. PubMed ID: 15870972
[TBL] [Abstract][Full Text] [Related]
16. Colon-Targeted Therapy of Tacrolimus (FK506) in the Treatment of Experimentally Induced Colitis.
Ali AS; Altayari AA; Khan LM; Alharthi SE; Ahmed OA; El-Shitany NA; Ali SS; Saadah OI
Pharmacology; 2020; 105(9-10):541-549. PubMed ID: 31940656
[TBL] [Abstract][Full Text] [Related]
17. Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis.
Bautzová T; Rabišková M; Béduneau A; Pellequer Y; Lamprecht A
Eur J Pharm Biopharm; 2012 Jun; 81(2):379-85. PubMed ID: 22386911
[TBL] [Abstract][Full Text] [Related]
18. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease.
Yadav VR; Suresh S; Devi K; Yadav S
J Pharm Pharmacol; 2009 Mar; 61(3):311-21. PubMed ID: 19222903
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
[TBL] [Abstract][Full Text] [Related]
20. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease.
Bhavsar MD; Amiji MM
Gene Ther; 2008 Sep; 15(17):1200-9. PubMed ID: 18418416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
